Skip to main content
Figure 4 | BMC Pharmacology

Figure 4

From: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

Figure 4

Doxycycline does not decrease tumor growth or increase survival in nude mice bearing Tsc2-/- tumors. (a) Average tumor growth over time for doxycycline and doxycycline plus rapamycin treated animals. Error bars shown indicate standard error. (b) Survival over time for doxycycline and doxycycline plus rapamycin cohorts. Based on survival analysis and comparison of tumor volumes on days 26 and 42, doxycycline was not effective as a single agent or in combination with rapamycin in this preclinical study. This data is summarized in Table 5.

Back to article page

BMC Pharmacology

ISSN: 1471-2210